Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct 6;12(10):1601-1614.
doi: 10.2215/CJN.02490317. Epub 2017 Sep 6.

Effectiveness of Quality Improvement Strategies for the Management of CKD: A Meta-Analysis

Affiliations
Review

Effectiveness of Quality Improvement Strategies for the Management of CKD: A Meta-Analysis

Samuel A Silver et al. Clin J Am Soc Nephrol. .

Abstract

Background and objectives: Quality improvement interventions have enhanced care for other chronic illnesses, but their effectiveness for patients with CKD is unknown. We sought to determine the effects of quality improvement strategies on clinical outcomes in adult patients with nondialysis-requiring CKD.

Design, setting, participants, & measurements: We conducted a systematic review of randomized trials, searching Medline and the Cochrane Effective Practice and Organization of Care database from January of 2003 to April of 2015. Eligible studies evaluated one or more of 11 prespecified quality improvement strategies, and prespecified study outcomes included at least one process of care measure, surrogate outcome, or hard clinical outcome. We used a random effects model to estimate the pooled risk ratio (RR; dichotomous data) or the mean difference (continuous data).

Results: We reviewed 15 patient-level randomized trials (n=3298 patients), and six cluster-randomized trials (n=30,042 patients). Quality improvement strategies reduced dialysis incidence (seven trials; RR, 0.85; 95% confidence interval [95% CI], 0.74 to 0.97) and LDL cholesterol concentrations (four trials; mean difference, -17.6 mg/dl; 95% CI, -28.7 to -6.5), and increased the likelihood that patients received renin-angiotensin-aldosterone system inhibitors (nine trials; RR, 1.16; 95% CI, 1.06 to 1.27). We did not observe statistically significant effects on mortality, cardiovascular events, eGFR, glycated hemoglobin, and systolic or diastolic BP.

Conclusions: Quality improvement interventions yielded significant beneficial effects on three elements of CKD care. Estimates of the effectiveness of quality improvement strategies were limited by study number and adherence to quality improvement principles.

Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2017_09_06_CJASNPodcast_17_10.mp3.

Keywords: Adult; Cholesterol, LDL; Chronic Disease; Confidence Intervals; Disease Management; Hemoglobin A, Glycosylated; Humans; Incidence; Odds Ratio; Probability; Quality Improvement; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renin-Angiotensin System; Risk; blood pressure; chronic kidney disease; chronic kidney failure; glomerular filtration rate; quality improvement; renal dialysis.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
PRISMA flow diagram of included studies.
Figure 2.
Figure 2.
Results of meta-analyses for prespecified outcomes and process measures. 95% CI, 95% confidence interval; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; IV, inverse variance; M-H, Mantel-Haenszel.
Figure 2.
Figure 2.
Results of meta-analyses for prespecified outcomes and process measures. 95% CI, 95% confidence interval; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; IV, inverse variance; M-H, Mantel-Haenszel.
Figure 2.
Figure 2.
Results of meta-analyses for prespecified outcomes and process measures. 95% CI, 95% confidence interval; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; IV, inverse variance; M-H, Mantel-Haenszel.

Similar articles

Cited by

References

    1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047, 2007 - PubMed
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group : KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3: 1–150, 2013
    1. Allen AS, Forman JP, Orav EJ, Bates DW, Denker BM, Sequist TD: Primary care management of chronic kidney disease. J Gen Intern Med 26: 386–392, 2011 - PMC - PubMed
    1. Charles RF, Powe NR, Jaar BG, Troll MU, Parekh RS, Boulware LE: Clinical testing patterns and cost implications of variation in the evaluation of CKD among US physicians. Am J Kidney Dis 54: 227–237, 2009 - PMC - PubMed
    1. Philipneri MD, Rocca Rey LA, Schnitzler MA, Abbott KC, Brennan DC, Takemoto SK, Buchanan PM, Burroughs TE, Willoughby LM, Lentine KL: Delivery patterns of recommended chronic kidney disease care in clinical practice: Administrative claims-based analysis and systematic literature review. Clin Exp Nephrol 12: 41–52, 2008 - PubMed

MeSH terms